TD Cowen Maintains Buy on Medline, Lowers Price Target to $45
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Charles Rhyee maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $53 to $45.
TD Cowen analyst Charles Rhyee maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $53 to $45.